Development and Evaluation of Paclitaxel‐Loaded Self‐Nanoemulsifying Drug Delivery System for Enhanced Cancer Therapy: A Promising Alternative to Cremophor EL–Based Formulation
IET Nanobiotechnology · 2026-01 · 2026 (1)
DOI: 10.1049/nbt2/4890307 ↗Kurz gefasst
Fachartikel in der Zeitschrift IET Nanobiotechnology, online erschienen am 22.05.2026. Verfasst von Alshaimaa M. Almehmady und 6 weiteren Autor:innen. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: King Abdulaziz University.
Abstract (Originalsprache)
Background and Purpose Paclitaxel’s clinical use is limited by poor aqueous solubility and Cremophor EL–related toxicity in commercial formulations. This study aimed to develop a self‐nanoemulsifying drug delivery system (SNEDDS) to improve paclitaxel solubility, bioavailability, and anticancer efficacy. Experimental Approach Paclitaxel‐loaded SNEDDSs were prepared using oleic acid, Tween 80, and polyethylene glycol (PEG) 400 in different ratios and characterized for particle size, polydispersity index (PDI), zeta potential, and solubility. The optimized formulation (F1) was assessed for cytotoxicity, cell cycle distribution, apoptosis, mitochondrial membrane potential (MMP), and nuclear morphology in MCF‐7 breast cancer cells. Key Results Formulation F1 (10% oleic acid, 10% PEG 400, and 80% Tween 80) exhibited the highest solubility, smallest particle size, and lowest PDI, with near‐neutral zeta potential ensuring stability. F1 demonstrated superior cytotoxic activity, inducing G 2 /M arrest (41.8%) and total apoptosis of 70.6%, mainly in the early phase (64.4%), compared to pure paclitaxel and Paxol. MMP and 4 ′ , 6‐diamidino‐2‐phenylindole (DAPI) assays confirmed mitochondrial‐mediated apoptosis and nuclear fragmentation, consistent with paclitaxel’s mechanism of microtubule stabilization and mitotic catastrophe. Conclusion and Implications Encapsulation of paclitaxel into SNEDDS significantly enhanced solubility, cellular uptake, and proapoptotic activity. The optimized F1 formulation provides a promising nanocarrier platform for improving paclitaxel’s therapeutic performance and may serve as a safer, more effective alternative to Cremophor EL–based products for breast cancer treatment.
Förderung
- King Abdulaziz University
Zitieren
APA
Almehmady, A. M., Alahmadi, A. A., Hakami, A., Ali, E. M. M., Kalantan, A. A., Aljagthmi, A., & Ahmed, T. A. (2026). Development and Evaluation of Paclitaxel‐Loaded Self‐Nanoemulsifying Drug Delivery System for Enhanced Cancer Therapy: A Promising Alternative to Cremophor EL–Based Formulation. IET Nanobiotechnology, 2026(1). https://doi.org/10.1049/nbt2/4890307
Vancouver
Almehmady AM, Alahmadi AA, Hakami A, Ali EMM, Kalantan AA, Aljagthmi A, et al. Development and Evaluation of Paclitaxel‐Loaded Self‐Nanoemulsifying Drug Delivery System for Enhanced Cancer Therapy: A Promising Alternative to Cremophor EL–Based Formulation. IET Nanobiotechnology. 2026;2026(1). doi:10.1049/nbt2/4890307
BibTeX
@article{Almehmady2026,
author = {Almehmady, Alshaimaa M. and Alahmadi, Amerh A. and Hakami, Abrar and Ali, Ehab M. M. and Kalantan, Abdulaziz A. and Aljagthmi, Amjad and Ahmed, Tarek A.},
title = {Development and Evaluation of Paclitaxel‐Loaded Self‐Nanoemulsifying Drug Delivery System for Enhanced Cancer Therapy: A Promising Alternative to Cremophor EL–Based Formulation},
journal = {IET Nanobiotechnology},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1049/nbt2/4890307}
}
EUVIMED